午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

belatacept

belatacept Struktur
706808-37-9
CAS-Nr.
706808-37-9
Englisch Name:
belatacept
Synonyma:
belatacept;Research Grade Belatacept;Research Grade Belatacept (DHE03402)
CBNumber:
CB51508591
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

belatacept Eigenschaften

Aggregatzustand
Solid
Farbe
White to off-white

Sicherheit

belatacept Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Belatacept is an immunosuppressive that was approved by the U.S. FDA for prophylactic prevention of rejection in kidney transplant recipients. Belatacept, which selectively blocks T cell costimulation, provides an alternative to the calcineurin inhibitors, which are associated with adverse effects on renal function as well as cardiovascular and metabolic parameters. T-cell activation by antigen-presenting cells (APCs) requires a costimulatory signal in addition to the signal mediated by interaction of the T-cell receptor and MHC-bound peptide antigen. Belatacept can block that second signal by binding to APC costimulatory surface proteins CD80 and CD86 to inhibit their interaction with the T-cell signaling molecule CD28. Belatacept is a recombinant protein comprising a hinge-region modified (to reduce Fc receptor binding) carboxylterminal human IgG1 Fc domain fused to a modified extracellular domain of human CTLA-4 that includes two amino acid substitutions in the ligand-binding site. As a result of this modification, belatacept binds more tightly to CD80 and CD86 than the parent molecule abatacept (Orencia, FDA approved for treatment of adult RA and juvenile idiopathic arthritis), from which its structure is derived. CTLA-4 is a T-cell negative signaling molecule that is structurally related to CD28 and shares its two ligands. While belatacept incorporates CTLA-4 sequences to bind CD80 and CD86, the immunosuppressive activity of the drug suggests that its principal mechanism of action is blockade of CD28-mediated T-cell activation.

Verwenden

Prevention of allograft rejection in recipients of solid organ transplants; prevention of graft-vs-host disease following bone marrow transplantation; treatment of autoimmune diseases and conditions such as rheumatoid arthritis and Type 1 diabetes.

belatacept Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


belatacept Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 6)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
BOC Sciences 1-631-485-4226; 16314854226
info@bocsci.com United States 12952 65
Wuhan Chemstan Biotechnology Co., Ltd. 027-65317797 15926423062
422450190@qq.com China 10308 58
Biolab Reagents 18108604356 18108604356
info@biolabreagent.com China 9868 58
TargetMol Chemicals Inc. 15002134094
marketing@targetmol.cn China 20614 58
Atagenix Laboratories 027-87008169 17762441161
info@atagenix.com China 9914 58
AntibodySystem Laboratories SAS 33175446423
support@antibodysystem.com China 6739 58

  • belatacept
  • Research Grade Belatacept (DHE03402)
  • Research Grade Belatacept
  • 706808-37-9
Copyright 2019 ? ChemicalBook. All rights reserved